Pulmonary Disease in Annapolis, MD
5 verified pulmonary disease doctors in Annapolis.
Pulmonologists diagnose and treat diseases of the lungs and respiratory system, such as asthma, COPD, and sleep apnea.
NPPES tenure ≠ clinical experience. "Years on NPPES" is time since the physician first registered a National Provider Identifier, not time practicing medicine. Verify current license status with the state medical board.
Dr. Steven Resnick, MD
Pulmonary Disease
CMS Open Payments· $2,704 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$2,704
Total received
122
Transactions
26
Paying companies
Top paying companies
Among the 13,317 pulmonary disease doctors we've analyzed, about 54% received any industry payment (median $474 among those who did). This doctor's total ranks around the 88th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US pulmonary disease doctors.
Payments to Steven Resnick do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Sjoerd Beck, MD
Pulmonary Disease
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.
Dr. Robert Peterson, MD
Pulmonary Disease
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.
Dr. Stanley Krimins, MD
Pulmonary Disease
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.
Dr. Stuart Tomares, MD
Pulmonary Disease
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.